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 BACKGROUND 
 Paediatric stroke is defi ned as a stroke occurring in patients 
who are between 1 month and 18 years of age, is an 
under-recognised, potentially treatable cause of childhood 
neurologic disease with a misconception that it is a rare 
childhood disorder. Approximately 2–6/100 000 children 
are affected annually, and is one of the top ten causes of 
childhood death. 1 – 4 Limited awareness regarding paedi-
atric stroke among paediatricians and in community is a 
major issue once that stroke symptoms are attributed fre-
quently to stroke-mimickers such as migraine, encephalitis, 
tumours and postictal Todd paralysis, which can account 
for up to one fi fth of cases presenting with stroke-like 
symptoms. 5  6 
 The mechanism of vertebro-basilar ischaemia had not 
been adequately studied until a few years ago; its occlu-
sion is usually a life-threatening disease leading to death 
or major disability and is very rare in paediatric age. 7 – 9 
Although recanalisation with thrombolytic agent has sub-
stantially improved outcomes in adults, in children the role 
of thrombolysis remains to be determined. 10 
 We report a case of a 13-year-old adolescent who suf-
fered an acute ischaemic stroke (AIS), due to acute basilar 
artery thrombosis, successfully treated with intravenous 
recombinant tissue plasminogen activator (rt-PA). 
 CASE PRESENTATION 
 A 13-year-old female adolescent, right-handed presented 
to the emergency department with 21 h history of a dif-
fuse onset of headache, nausea and vomitting and a 2 h of 
diplopia. Her history was unremarkable, with no history 
of trauma or neck manipulation, no history of taking oral 
contraceptives neither alcohol, smoking or illicit drug use. 
There was no family history of early stroke, haematologic, 
vascular or metabolic disorders. 
 Physical and neurologic examination showed mental 
confusion, right facial upper motor neuron weakness and 
mild left hemiparesis, followed by a rapid decreasing level 
of consciousness to a stuporous state and decorticate pos-
turing. A clinical diagnosis of acute brainstem ischaemia 
was suspected. A CT scan was performed and showed a 
hyperdensity of the distal third part of basilar artery, with 
no opacifi cation after contrast injection, features consistent 
with acute basilar thrombosis ( fi gure 1A,B ). 
 After discussion with the adult cerebrovascular inten-
sive care unit and paediatric neurology, it was decided to 
recommend the administration of intravenous rt-PA to 
the patient. After obtaining informed consent from the 
parents, with a complete explanation of the benefi ts and 
risks, including death, and a discussion of the lack of evi-
dence for this treatment for children, intravenous alteplase 
was given. Because no procedure for the administration of 
rt-PA to children exists at our institution, we followed the 
adult stroke protocol, which result in a intravenous infu-
sion of 63 mg of rt-PA (0 9 mg/kg). 
 The patient was locked-in for about 24 h, after that her 
condition dramatically improved, with recovering of the 
hemiparesis and diplopia, however she remained with 
dysarthria. 
 Subsequent laboratory evaluation included a normal 
complete blood count and smears, electrolytes, urea, creat-
inine and serum lipids. The toxicology screen was negative 
for cocaine, amphetamines, ethanol, cyclic antidepressants, 
paracetamol and salicylates. Auto-immune and hyperco-
agulable screen including antinuclear, antiphospholipid 
antibodies, proteins C and S defi ciency, factor V Leiden, 
antithrombin III defi ciency and lupus anticoagulant were 
negative. Serum and urine amino acids and urine organic 
acids were normal. Frequent infectious agents such as par-
vovirus B19, Cytomegalovirus,  Mycoplasma pneumoniae , 
 Borrelia burgdorferi , enterovirus, HIV were discharged. A 
neck blood vessels echo-Doppler was normal and trans-
esophageal echocardiography showed an atrial septal 
defect (ASD), ostium secundum type measuring 17 mm of 
diameter, with left-to-right systo-diastolic non-restrictive 
shunt; in the doubt of the ASD be regarded as an incidental 
fi nding, it was decided to initiate anticoagulation with war-
farin until its closure. Molecular diagnosis of thrombophilia 
and warfarin pharmacogenetics showed homozygous 
angiotensin-converting enzyme delection/delection, and 
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heterozygous plasminogen activator inhibitor-1 genotype 
-844 A and -675 4G/5G genotype polymorphisms. 
 After a period of rehabilitation, the patient was dis-
charged with resolution of dysarthria and normal neuro-
logical examination. The patient had an angio-MRI brain 
control 2 months after discharge which showed a total per-
meabilisation of the basilar artery and a small pons seque-
lae infarct ( fi gures 2 and  3 ). 
 DISCUSSION 
 The incidence of ischaemic stroke in childhood is estimated 
to be 2–7.91/100 000 children/year, is an under-recognised, 
potentially treatable cause of childhood neurologic disease 
with a misconception that is a rare childhood disorder. 1 – 4 
 Limited awareness regarding paediatric stroke among 
paediatricians and in community is a major issue once 
that stroke symptoms are attributed frequently to stroke-
mimickers such as migraine, encephalitis, tumours and 
postictal Todd paralysis, which can account for up to one 
fi fth of cases presenting with stroke-like symptoms. 5  6 
 Morbidity and mortality from paediatric stroke is sub-
stantial, being one of the top ten causes of childhood 
death. At least half of children will develop sensory or 
motor problems, seizure, development delay or cognitive 
disorders; 15% die and 35% are neurologically normal. 
The outcome and recurrence risk depend on the underly-
ing cause. No risk factors will be identifi able in approxi-
mately 25% of children with stroke. 11 – 14 
 Childhood stroke may be ischaemic or haemorrhagic, 
although ischaemic stroke is far more common. 15 The 
mechanism of vertebro-basilar ischaemia had not been 
adequately studied until a few years ago; its occlusion is 
usually a life-threatening disease leading to death or major 
disability and is very rare in paediatric age 7–8  10 
 Acute management to restore cerebral blood fl ow 
improve prognosis and are nowadays a reality in the inter-
vention of adult stroke. 16 Although that in adults, in chil-
dren there are no guidelines based on clinical trials for acute 
management of childhood stroke, with exception of sickle 
cell disease so, the role of thrombolysis in children stroke 
remains to be determined, and adult guidelines cannot be 
extrapolated to children due to age-related differences in 
cerebrovascular, neurological and coagulation system, as 
well in causes and pathophysiology. 10 
 The thrombolytic agent of choice in children may be 
alteplase, compared with other agents that include evi-
dence of increased thrombolysis invitro, decreased immu-
nogenicity, higher fi brin selectivity and better side effect 
profi le. 17  18 
 The Thrombolysis in Paediatric Stroke study is a clinical 
trial to asses the safety of intravenous t-PA and intra-arterial 
in children with AIS. Doses for intravenous t-PA will start 
at 0.6 mg/kg and escalate to 1.0 mg/kg depending on toxic-
ity. The intra-arterial t-PA dose will range from 0.2 to 0.5 
mg/kg. Inclusion criteria include 0–3 h from onset of stroke 
for treatment with intravenous t-PA and 3–6 h from stroke 
onset for intra-arterial t-PA; and signifi cant neurological 
 Figure 2  Brain MRI: small pons sequelae infarct. 
 Figure 1  (A) Hyperdensity of the distal third part of basilar 
artery, with no opacifi cation after contrast injection. (B) 
Hyperdensity of the distal third part of basilar artery, with no 
opacifi cation after contrast injection. 
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damage defi ned as ≥10 or ≤30 on the paediatric version 
of the National Institute of Health Stroke Scale that is not 
improving is required before t-PA administration. 19 
 In our patient, treatment with intravenous rt-PA was 
considered, after parents’ informed consent and unani-
mous agreement of the physicians involved, because the 
prognosis of basilar occlusion was so bad that the risks 
could be tolerated and ethically justifi ed. Multiple cases 
of successful late interventions in arterial stroke have been 
documented, including good outcomes with interventions 
up to 80 h after symptoms onset, with better outcomes 
with intra-arterial thrombolysis. 20  21 
 Pre-existing cardiac disease, particularly complex con-
genital malformations with right to left shunts, can account 
for up to one third of the AIS in children 1  22 
 However, the contribution of a paradoxical embo-
lus through an isolated patent foramen ovale (PFO) as a 
risk factor for AIS in children is not well established and 
remains contentious. PFO is essentially considered a nor-
mal variant being found in approximately 25% of the gen-
eral population. 23 
 Infarcts of cardiac disease are usually with typical 
peripheral involving the cortex and subcortical white mat-
ter of both the anterior and posterior circulation. 1 
 In our case, the doubt of the ASD be regarded as an inci-
dental fi nding, it was decided to initiate anticoagulation 
with warfarin until its closure. 
 In paediatric stroke it is important to clarify all of the 
risk factors and possible causes, for that it was consider-
able to perform a molecular study of thrombophilia and 
warfarin pharmacogenetics which result a homozygous 
angiotensin-converting enzyme delection/delection, and 
heterozygous plasminogen activator inhibitor-1 genotype 
-844 A and -675 4G/5G polymorphisms. In some studies 
those polymorphisms were shown to be a risk factor for 
cerebral infarction, however the impact of thrombophilia 
in childhood stroke still remains unclear. 24 – 26 
 We were unable to identify an underlying cause for our 
patient’s stroke, but all of the predisposing factors for arte-
rial ischaemic stroke were evaluated. 10 
 Our report focuses attention on the striking and success-
ful treatment of an adolescent with acute thrombotic basi-
lar stroke using intravenous alteplase. 
 Learning points 
 ▶  Limited awareness regarding paediatric stroke among 
paediatricians and in are attributed frequently to 
stroke-mimickers such as migraine, encephalitis, 
tumours and postictal Todd paralysis. 
 In paediatric stroke it is important to clarify all of the  ▶
risk factors and possible causes. 
 Despite the small number of cases reported on  ▶
thrombolysis of paediatric stroke, the favourable 
outcome reinforces that thrombolytic therapy should 
not be withheld in case of life-threatening or potentially 
disabling paediatric stroke. 
 Competing interests  None. 
 Patient consent  Obtained. 
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